Clinical trial
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction: a Multicenter Randomized Double-blind Placebo-controlled Trial (OPTIMA-6)
NCT05410925 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction: a Multicenter Randomized Double-blind Placebo-controlled Trial (OPTIMA-6)
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- April 8, 2023
- Completion date
- December 31, 2027
- Enrollment
- 2,260 (estimated)
- Sites
- 61
Conditions
As the registry lists them; a condition with its own page is linked.